These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Potential and clinical translation of oncolytic measles viruses. Robinson S; Galanis E Expert Opin Biol Ther; 2017 Mar; 17(3):353-363. PubMed ID: 28129716 [TBL] [Abstract][Full Text] [Related]
46. Attenuated oncolytic measles virus strains as cancer therapeutics. Msaouel P; Iankov ID; Dispenzieri A; Galanis E Curr Pharm Biotechnol; 2012 Jul; 13(9):1732-41. PubMed ID: 21740361 [TBL] [Abstract][Full Text] [Related]
47. Mutations in the glycoprotein of vesicular stomatitis virus affect cytopathogenicity: potential for oncolytic virotherapy. Janelle V; Brassard F; Lapierre P; Lamarre A; Poliquin L J Virol; 2011 Jul; 85(13):6513-20. PubMed ID: 21561919 [TBL] [Abstract][Full Text] [Related]
48. Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity. Castleton A; Dey A; Beaton B; Patel B; Aucher A; Davis DM; Fielding AK Blood; 2014 Feb; 123(9):1327-35. PubMed ID: 24345754 [TBL] [Abstract][Full Text] [Related]
49. Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors. Roulstone V; Khan K; Pandha HS; Rudman S; Coffey M; Gill GM; Melcher AA; Vile R; Harrington KJ; de Bono J; Spicer J Clin Cancer Res; 2015 Mar; 21(6):1305-12. PubMed ID: 25424857 [TBL] [Abstract][Full Text] [Related]
50. The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma. Kimpel J; Urbiola C; Koske I; Tober R; Banki Z; Wollmann G; von Laer D Viruses; 2018 Mar; 10(3):. PubMed ID: 29498639 [TBL] [Abstract][Full Text] [Related]
51. In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity. Jenner AL; Cassidy T; Belaid K; Bourgeois-Daigneault MC; Craig M J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33608375 [TBL] [Abstract][Full Text] [Related]
52. Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus. Wongthida P; Diaz RM; Pulido C; Rommelfanger D; Galivo F; Kaluza K; Kottke T; Thompson J; Melcher A; Vile R Hum Gene Ther; 2011 Nov; 22(11):1343-53. PubMed ID: 21366404 [TBL] [Abstract][Full Text] [Related]
53. A tool with many applications: vesicular stomatitis virus in research and medicine. Munis AM; Bentley EM; Takeuchi Y Expert Opin Biol Ther; 2020 Oct; 20(10):1187-1201. PubMed ID: 32602788 [TBL] [Abstract][Full Text] [Related]
54. Protocols to Manufacture an Oncolytic Measles Virus-Sensitive Immunocompetent Mouse Model of Medulloblastoma. Lal S; Raffel C Methods Mol Biol; 2022; 2423():165-177. PubMed ID: 34978698 [TBL] [Abstract][Full Text] [Related]
55. Differential infection of murine and human dendritic cell subsets by oncolytic vesicular stomatitis virus variants. Pipperger L; Riepler L; Kimpel J; Siller A; Stoitzner P; Bánki Z; von Laer D Oncoimmunology; 2021; 10(1):1959140. PubMed ID: 34484872 [TBL] [Abstract][Full Text] [Related]
56. Oncolytic measles virus efficacy in murine xenograft models of atypical teratoid rhabdoid tumors. Studebaker AW; Hutzen B; Pierson CR; Shaffer TA; Raffel C; Jackson EM Neuro Oncol; 2015 Dec; 17(12):1568-77. PubMed ID: 25838138 [TBL] [Abstract][Full Text] [Related]
57. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Galanis E; Hartmann LC; Cliby WA; Long HJ; Peethambaram PP; Barrette BA; Kaur JS; Haluska PJ; Aderca I; Zollman PJ; Sloan JA; Keeney G; Atherton PJ; Podratz KC; Dowdy SC; Stanhope CR; Wilson TO; Federspiel MJ; Peng KW; Russell SJ Cancer Res; 2010 Feb; 70(3):875-82. PubMed ID: 20103634 [TBL] [Abstract][Full Text] [Related]
58. Oncolytic Recombinant Vesicular Stomatitis Virus (VSV) Is Nonpathogenic and Nontransmissible in Pigs, a Natural Host of VSV. Velazquez-Salinas L; Naik S; Pauszek SJ; Peng KW; Russell SJ; Rodriguez LL Hum Gene Ther Clin Dev; 2017 Jun; 28(2):108-115. PubMed ID: 28514874 [TBL] [Abstract][Full Text] [Related]
59. Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy. Bishnoi S; Tiwari R; Gupta S; Byrareddy SN; Nayak D Viruses; 2018 Feb; 10(2):. PubMed ID: 29473868 [TBL] [Abstract][Full Text] [Related]
60. Induction of apoptosis in pancreatic cancer cells by vesicular stomatitis virus. Felt SA; Moerdyk-Schauwecker MJ; Grdzelishvili VZ Virology; 2015 Jan; 474():163-73. PubMed ID: 25463614 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]